ArticleMedical oncology (Northwood, London, England)2025
Investigation of the possible effects of LncRNA CYTOR on the molecular mechanisms of metastasis and Hippo signaling pathways in Triple-negative and Cisplatin-resistant breast cancer cell lines.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the functional landscape of long non-coding RNAs in hepatocellular carcinoma: molecular mechanisms, clinical implications, and therapeutic prospects.Journal of the Egyptian National Cancer Institute · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer is one of the cancers with the highest incidence among women worldwide. Increasing evidence suggests that the long noncoding RNA cytoskeleton regulator (CYTOR) plays a critical role in cancers and is upregulated in many cancer types. In this study, the effects of siRNA inhibition of CYTOR, a long non-coding RNA (LncRNA), on cell viability, apoptosis, Hippo signaling pathway and molecular mechanisms involved in metastasis were investigated in breast cancer cell lines. The suppressive effects of CYTOR on cell proliferation in MDA-MB-231 and HCC1428 cells were determined by the 3-(4,5-Dimethyltriazol-2-yl)-2.5 diphenyltetrazolium bromide (MTT) method. Scratch assay, colony formation assay, migration and invasion tests, were performed to determine the effects of CYTOR on the proliferation and migration of MDA-MB-231 and HCC1428 cells. In addition, its effects on apoptotic (Bax, Bcl-2), Hippo and metastatic genes (YAP1, MST1, LATS1, CTGF, ECAD, NCAD) were determined using quantitative real-time polymerase chain reaction (qRT-PCR). As a result of the study, CYTOR expression was suppressed by 80% with siCYTOR-779 in MDA-MB-231 cells and by 88% with siCYTOR-572 in HCC1428 cells. The CYTOR suppression significantly inhibited cell proliferation, cell colony formation and migration of breast cancer cells. It was also determined that CYTOR suppression caused a decrease in the expression of the YAP1 gene, a key effector of the Hippo signaling pathway and the CTGF gene, one of its target genes. In conclusion, our findings suggest that CYTOR may be a potential therapeutic target in breast cancer by regulating the Hippo signaling pathway.
Indexed as
Identifiers
41455878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.